However, silencing ROR2 in human breast cancer cell lines decreased both β-catenin-dependent and β-catenin-independent targets [47], suggesting that ROR2 may be involved in both β-catenin-dependent and β-catenin-independent Wnt signaling pathways. Here, ROR2 is linked to breast carcinoma.